S
Samuel D Vasikaran
Researcher at Royal Perth Hospital
Publications - 110
Citations - 5193
Samuel D Vasikaran is an academic researcher from Royal Perth Hospital. The author has contributed to research in topics: Osteoporosis & N-terminal telopeptide. The author has an hindex of 33, co-authored 103 publications receiving 4801 citations. Previous affiliations of Samuel D Vasikaran include Fiona Stanley Hospital & University of Western Australia.
Papers
More filters
Journal ArticleDOI
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
Samuel D Vasikaran,Samuel D Vasikaran,Richard Eastell,Olivier Bruyère,A. J. Foldes,P. Garnero,Andrea Griesmacher,Michael R. McClung,Howard A. Morris,Stuart L. Silverman,Tommaso Trenti,D. A. Wahl,Cyrus Cooper,Cyrus Cooper,John A. Kanis +14 more
TL;DR: BTM hold promise in fracture risk prediction and for monitoring treatment and Uncertainties over their clinical use can be in part resolved by adopting international reference standards.
Journal ArticleDOI
The assessment of vertebral deformity: a method for use in population studies and clinical trials
Eugene V. McCloskey,Tim D. Spector,K. S. Eyres,E.D. Fern,N. O'Rourke,Samuel D Vasikaran,J. A. Kanis +6 more
TL;DR: Radiological criteria for vertebral fracture in women for assessing both the prevalence and the incidence of vertebral osteoporosis in population and in prospective studies has a high specificity, and reduces the impact of errors of reproducibility on estimates of prevalence and incidence.
Journal ArticleDOI
Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis
S. Khan,John A. Kanis,Samuel D Vasikaran,W. F. Kline,Bogdan K. Matuszewski,Eugene V. McCloskey,Monique N.C. Beneton,Barry J. Gertz,David G. Sciberras,Sherry D. Holland,J. Orgee,G. Coombes,S. Rogers,Arturo G. Porras +13 more
TL;DR: It is concluded that a short course of high doses of intravenous alendronate is associated with a prolonged skeletal retention of the agent, and suggests that this regimen has a sustained effect on bone turnover persisting for at least 1 year.
Journal ArticleDOI
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis.
Samuel D Vasikaran,Cyrus Cooper,Richard Eastell,Andrea Griesmacher,Howard A. Morris,Tommaso Trenti,John A. Kanis +6 more
TL;DR: The IOF/IFCC recommends one bone formation marker and one bone resorption marker to be used as reference markers and measured by standardised assays in observational and intervention studies to enlarge the international experience of the application of markers to clinical medicine and to help resolve uncertainties over their clinical use.
Journal ArticleDOI
Methylenetetrahydrofolate reductase gene and coronary artery disease
TL;DR: The data suggest that a mutation of the MTHFR gene, which has been associated with a thermolabile form of the enzyme and with hyperhomocysteinemia in subjects with plasma folate below the median, does not appear to be significantly associated with risk for premature coronary artery disease or for restenosis after coronary angioplasty.